Jounce Therapeutics (JNCE) Getting Somewhat Favorable Media Coverage, Accern Reports

News headlines about Jounce Therapeutics (NASDAQ:JNCE) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Jounce Therapeutics earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.8178333383946 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Shares of Jounce Therapeutics (NASDAQ JNCE) opened at $13.71 on Wednesday. Jounce Therapeutics has a 12-month low of $11.05 and a 12-month high of $29.29.

Jounce Therapeutics (NASDAQ:JNCE) last posted its quarterly earnings data on Monday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.12. Jounce Therapeutics had a negative return on equity of 1.39% and a negative net margin of 2.03%. The company had revenue of $18.10 million for the quarter, compared to analysts’ expectations of $20.00 million. Jounce Therapeutics’s revenue was up 7.1% on a year-over-year basis. sell-side analysts expect that Jounce Therapeutics will post -0.86 EPS for the current year.

JNCE has been the subject of a number of recent research reports. Zacks Investment Research upgraded Jounce Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 15th. J P Morgan Chase & Co set a $28.00 price objective on Jounce Therapeutics and gave the company a “buy” rating in a research note on Monday, November 13th. Finally, Robert W. Baird reiterated a “buy” rating and set a $30.00 price objective on shares of Jounce Therapeutics in a research note on Friday, November 10th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $23.67.

TRADEMARK VIOLATION WARNING: “Jounce Therapeutics (JNCE) Getting Somewhat Favorable Media Coverage, Accern Reports” was originally published by Week Herald and is owned by of Week Herald. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://weekherald.com/2017/12/13/jounce-therapeutics-jnce-receiving-somewhat-positive-news-coverage-report-shows.html.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.

Insider Buying and Selling by Quarter for Jounce Therapeutics (NASDAQ:JNCE)

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply